Skip to main content

BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales

Submitted by admin on
snippet

On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime opportunity.” To him, the company’s potential in chronic lymphocytic leukemia is akin to two other legendary Big Biotech stories—Gilead in HIV and Vertex in cystic fibrosis.

Source
Fierce Pharma

[podcast]Brukinsa approval raises BeiGene’s hematology profile

Submitted by admin on
snippet

BeiGene’s chief medical officer for hematology, Dr. Mehrdad Mobasher, tells Jack O’Brien about BTK inhibitor Brukinsa’s latest lymphoma approval from the FDA and offers messaging advice to medical marketers. 

Source
Medical Marketing and Media

FDA approves expanded use of BeiGene's blood cancer drug

Submitted by admin on
snippet

The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's (6160.HK) combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.

Source
Reuters

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

Submitted by admin on
snippet

In a new lawsuit, AbbVie’s Pharmacyclics unit contends BeiGene’s Brukinsa infringes a patent on its blood cancer drug Imbruvica. Both Imbruvica and Brukinsa are irreversible BTK inhibitors approved in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Source
Fierce Pharma

BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

Submitted by admin on
snippet

Thanks to cancer drugs Brukinsa and tislelizumab, BeiGene nearly doubled its global sales in 2022. But the most important launches for the meds either have just begun or are yet to come.

Source
Fierce Pharma

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

Submitted by admin on
snippet

The FDA greenlit BeiGene’s Brukinsa for use in chronic lymphocytic lymphoma, an approval that should substantially expand the market for the drug in the US after it topped the current leading therapy in a trial.

Source
Endpoints

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

Submitted by admin on
snippet

If yesterday’s Ash late-breaker on Beigene’s Brukinsa signalled a changing of the guard in primary BTK inhibition, earlier data from Lilly’s pirtobrutinib and Nurix’s NX-2127 highlighted potential new options for patients who relapse on current BTK drugs.

Source
EP Vantage

BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

Submitted by admin on
snippet

As BeiGene gears up for an all-out war against AbbVie and Johnson & Johnson’s Imbruvica, the company has turned in more clinical evidence to show it has the winning BTK inhibitor to fight certain blood cancers.

Source
Fierce Pharma

ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again

Submitted by admin on
snippet

As the third player to enter the BTK realm, BeiGene has had its eyes fixated on AbbVie and Johnson & Johnson’s market leader Imbruvica. After clinical wins in smaller indications, the Chinese-American biotech has once again posted competitive data for Brukinsa—this time in the all-important newly diagnosed leukemia.

Source
Fierce Biotech

FDA grants BeiGene's Brukinsa accelerated approval in marginal zone lymphoma

Submitted by admin on
snippet

BeiGene (NASDAQ:BGNE) announces that Brukinsa (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

Source
Seeking Alpha